Vericel Corp. (VCEL)

[hurley cruppers]

300 MACI procedures covers the nut possibly

Thanks, Nick. Total GAAP net revenues for the quarter ended June 30, 2017 were approximately $17 million and included approximately $12.9 million of MACI and Carticel net revenues and approximately $4.1 million of Epicel

12.9M divided by $43k per procedures is 300

Research and development expenses for the quarter were $3 million

Loss from operations for the quarter ended June 30th, 2017 were $2.5 million

If you remove the R&D expenses, VCEL is already profitable.

Sooner than later R&D is going to end, once the R&D expenses end from 2b crossover study, VCEL will be profitable on $12.9M gross MACI sales, plus the ongoing Epicel sales that was recorded.

This 3rd quarter aren't we expecting between 400 and 600 MACI procedures?

https://seekingalpha.com/article/4096867-vericels-vcel-ceo-nick-colangelo-q2-2017-results-earnings-call-transcript?part=single

VCEL